Highlights Reneo Pharmaceuticals, Inc.

Equities

RPHM

US75974E1038

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
1.83 ^USD	+5.17%		+7.02%	+14.38%

May. 07	Reneo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 28	Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Reneo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Concentra Biosciences, LLC submitted a non-binding proposal to acquire Reneo Pharmaceuticals, Inc. for $60 million.	Dec. 25	CI
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Reneo Pharmaceuticals, Inc. announces an Equity Buyback for 576,443 shares, for $4.4 million.	23-10-30	CI
Reneo Pharmaceuticals, Inc. authorizes a Buyback Plan.	23-10-29	CI
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
RENEO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-27	AQ
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-27	CI
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-27	CI
Reneo Pharmaceuticals, Inc. Achieves Target Enrollment in the Pivotal Stride Study of Mavodelpar in Primary Mitochondrial Myopathies	23-03-14	CI
Reneo Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Mavodelpar in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)	23-01-31	CI
RENEO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-11-08	AQ
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
RENEO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-08-09	AQ
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Reneo Pharmaceuticals, Inc. Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study	22-07-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Reneo Pharmaceuticals, Inc.

Equities

RPHM

US75974E1038

Highlights

Filters